The prostate is a walnut-sized gland located behind the base of a man's penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
The classification of Prostate Cancer Diagnostics includes Tumor Biomarker Tests, Imaging, Biopsy and other, and most of Prostate Cancer Diagnostics use the method of Biopsy, the proportion of Biopsy in 2017 is about 44.65%.
Prostate Cancer Diagnostics is widely used for the people with Prostate Cancer, The most proportion of Prostate Cancer Diagnostics is used for people with the age between 55 and 75, and the proportion is about 70.24% in 2017.
North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49.84% in 2017. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28% in 2017.

According to this study, over the next five years the Prostate Cancer Diagnostics market will register a 7.9% CAGR in terms of revenue, the global market size will reach US$ 15800 million by 2024, from US$ 10000 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Prostate Cancer Diagnostics business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Prostate Cancer Diagnostics market by product type, application, key manufacturers and key regions and countries.

This study considers the Prostate Cancer Diagnostics value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3: and forecast to 2024 in section 11.7.
Tumor Biomarker Tests
Imaging
Biopsy
Other
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4: and forecast to 2024 in section 11.8.
age < 55
age 55-75
age > 75

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Genomic Health
Abbott
OPKO
Siemens Healthcare
DiaSorin
BioMeriux
Roche
MDx Health
Beckman Coulter
Myriad Genetics
Ambry Genetics

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Prostate Cancer Diagnostics consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Prostate Cancer Diagnostics market by identifying its various subsegments.
Focuses on the key global Prostate Cancer Diagnostics manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Prostate Cancer Diagnostics with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Prostate Cancer Diagnostics submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.